These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12817768)

  • 1. The Food and Drug Administration's Osteoporosis Guidance Document: past, present, and future.
    Colman EG;
    J Bone Miner Res; 2003 Jun; 18(6):1125-8. PubMed ID: 12817768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study design in osteoporosis: a European perspective.
    Kanis JA; Alexandre JM; Bone HG; Abadie E; Brasseur D; Chassany O; Durrleman S; Lekkerkerker JF; Caulin F
    J Bone Miner Res; 2003 Jun; 18(6):1133-8. PubMed ID: 12817770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
    Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
    J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA regulation of the safety of MR devices: past, present, and future.
    Athey TW
    Magn Reson Imaging Clin N Am; 1998 Nov; 6(4):791-5. PubMed ID: 9799856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis: regulatory view.
    Sobel S
    Public Health Rep; 1987; 102(4 Suppl):136-9. PubMed ID: 3120212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
    Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
    Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance on submitting quality system information.
    Donawa ME
    Med Device Technol; 2004 Mar; 15(2):24-7. PubMed ID: 15154336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging the osteoporosis quality chasm.
    Curtis JR; Adachi JD; Saag KG
    J Bone Miner Res; 2009 Jan; 24(1):3-7. PubMed ID: 19016597
    [No Abstract]   [Full Text] [Related]  

  • 14. Compliance Guidance: The Mammography Quality Standards Act Final Regulations Document #1; availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(53):13590-1. PubMed ID: 10558407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the current regulatory environment on clinical research: An overview.
    Finlayson SR
    Surgery; 2009 Jun; 145(6):626-30. PubMed ID: 19486763
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of the Food and Drug Administration's Public Health Notification on the adoption of drug-eluting stents.
    Curtis JP; Cohen DJ; Jones PG; Bach RG; Spertus JA; Krumholz HM
    Am J Cardiol; 2007 May; 99(9):1227-9. PubMed ID: 17478147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint.
    Ley HL; Desmond FH
    Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100
    [No Abstract]   [Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.